[Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system]. / Neues zur Therapie von neuroendokrinen Tumoren des gastroenteropankreatischen Systems.

Current guidelines have been published for the diagnosis and therapy of neuroendocrine neoplasms of the gastroenteropancreatic (GEP) system 1. Systemic therapy of inoperable advanced neuroendocrine tumors includes biotherapy with somatostatin analogas, peptid receptor radionuclide therapy (PRRT) with 177Lutetium-DOTA-TATE, chemotherapy with steptozotocin/5-fluorouracil or capecitabine/temozolomide and molecular targeted therapy with everolimus or sunitinib 1 2. For symptom control in patients with carcinoid syndrome biotherapy with somatostatin analogs, PRRT, loco-regional and local-ablative interventional procedures of liver metastases as well as the peripheral serotonin synthesis inhibitor telotristat Ethyl 1 2 3 4 are highly effective. Novel aspects and developments in the diagnosis and treatment of neuroendocrine tumors will be discussed in this review.